Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD43 siRNA
- Development stage
- Preclinical
- Lead developer
- Gundersen Health System
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
CD43 siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of CD43 (sialophorin, SPN), a sialoglycoprotein normally restricted to leukocytes but aberrantly expressed in various cancers, including breast cancer, lung cancer, and leukemia. In breast cancer cells, CD43 is expressed in the cytoplasm and nucleus, where it promotes tumor progression, cell survival, and metastasis by regulating cell adhesion, migration, and resistance to apoptosis. Silencing CD43 with siRNA has been shown in preclinical models to increase cancer cell susceptibility to apoptosis and natural killer (NK) cell-mediated lysis, inhibit homotypic adhesion, and significantly reduce primary tumor growth in vivo. CD43 siRNA is primarily utilized as a research tool to investigate the oncogenic role of CD43 and evaluate its potential as a therapeutic target.
- Other names
- leukosialin siRNAsialophorin siRNASPN siRNA
02
Targets
CD43 (CD43 antigen)
Beyond the preview
Go deeper on CD43 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD43 siRNA.